• 1. Excellent electrochemical performance of LiFe0.4Mn0.6PO4 microspheres produced using a double carbon coating process?
  Yong Ping Huang,Tao Tao,Zheng Chen,Wei Han,Ying Wu,Chunjiang Kuang,Shaoxiong Zhou,Ying Chen J. Mater. Chem. A, 2014,2, 18831-18837
• 2. Enantiomeric helical TiO2 nanofibers modulate different peptide assemblies and subsequent cellular behaviors?
  Xu Jie,Deng Xu,Weili Wei RSC Adv., 2019,9, 29149-29153
• 3. Evidence of pre-micellar aggregates in aqueous solution of amphiphilic PDMS–PEO block copolymer?
  Domenico Lombardo,Gianmarco Munaò,Pietro Calandra,Luigi Pasqua,Maria Teresa Caccamo Phys. Chem. Chem. Phys., 2019,21, 11983-11991
• 4. Enantiomorphic symmetry breaking in crystallization of molten sodium chlorate?
  Martin R. Ward,Gary W. Copeland,Andrew J. Alexander Chem. Commun., 2010,46, 7634-7636
• 5. Evolved polymerases facilitate selection of fully 2′-OMe-modified aptamers?
  Zhixia Liu,Tingjian Chen,Floyd E. Romesberg Chem. Sci., 2017,8, 8179-8182

Research Brief on 2-Chloro-6-methyl-7H-pyrrolo[2,3-D]pyrimidine (CAS: 1060816-56-9): Recent Advances and Applications

The compound 2-Chloro-6-methyl-7H-pyrrolo[2,3-D]pyrimidine (CAS: 1060816-56-9) has recently emerged as a key intermediate in the synthesis of novel therapeutic agents, particularly in the field of kinase inhibitors and anticancer drug development. This heterocyclic scaffold has attracted significant attention due to its structural similarity to purine bases, allowing it to interact with various biological targets. Recent studies have demonstrated its potential in modulating critical signaling pathways involved in cell proliferation and survival.

In a 2023 study published in the Journal of Medicinal Chemistry, researchers utilized 2-Chloro-6-methyl-7H-pyrrolo[2,3-D]pyrimidine as a core structure to develop selective JAK2 inhibitors. The compound's chloro and methyl substituents at positions 2 and 6 respectively were found to be crucial for maintaining optimal binding affinity while allowing for further derivatization at the 7-position. The resulting inhibitors showed promising activity against myeloproliferative disorders in preclinical models, with improved pharmacokinetic properties compared to previous generations of JAK inhibitors.

Another significant application was reported in Bioorganic & Medicinal Chemistry Letters, where this pyrrolopyrimidine derivative served as a starting material for the synthesis of novel ALK5 inhibitors. The research team demonstrated that strategic modifications of the 2-chloro-6-methyl scaffold could yield compounds with enhanced selectivity for TGF-β signaling pathway inhibition, potentially offering new therapeutic options for fibrotic diseases and certain cancers. The study highlighted the compound's versatility as a building block for structure-activity relationship exploration.

Recent synthetic methodology developments have also focused on 2-Chloro-6-methyl-7H-pyrrolo[2,3-D]pyrimidine. A 2024 paper in Organic Process Research & Development described an improved, scalable synthesis route with higher yields and reduced environmental impact. The new protocol employs greener solvents and catalytic conditions, addressing previous challenges in large-scale production while maintaining the high purity required for pharmaceutical applications.

From a mechanistic perspective, computational studies have provided deeper insights into the molecular interactions of derivatives based on this scaffold. Molecular docking and dynamics simulations revealed that the chloro substituent at position 2 plays a critical role in forming halogen bonds with kinase hinge regions, while the methyl group at position 6 contributes to optimal hydrophobic interactions. These findings are guiding the rational design of next-generation inhibitors with improved target specificity.

The safety profile of 2-Chloro-6-methyl-7H-pyrrolo[2,3-D]pyrimidine has been extensively characterized in recent toxicological assessments. Studies conducted under Good Laboratory Practice (GLP) conditions have established appropriate handling procedures and safety measures for industrial and research applications. These data are particularly valuable as the compound sees increasing use in both academic and industrial drug discovery programs.

Looking forward, several clinical-stage compounds derived from this scaffold are expected to enter phase II trials in 2024-2025, particularly in oncology indications. The continued exploration of this chemical space demonstrates the enduring value of 2-Chloro-6-methyl-7H-pyrrolo[2,3-D]pyrimidine as a privileged structure in medicinal chemistry, with potential applications extending beyond its current uses to include emerging therapeutic areas such as targeted protein degradation and allosteric modulation.

• 35808-68-5(4-Chloro-6-methyl-7H-pyrrolo[2,3-d]pyrimidine)
• 1935224-57-9((2-Chloro-7H-pyrrolo[2,3-d]pyrimidin-6-yl)methanol)
• 92350-63-5(2,4-Dichloro-7-methyl-pyrido[2,3-d]pyrimidine)
• 1192711-71-9(2,4-Dichloro-6-methyl-7H-pyrrolo[2,3-d]pyrimidine)
• 1147014-54-7(2-chloro-4-ethynyl-7H-Pyrrolo[2,3-d]pyrimidine)
• 2761879-42-7(7H-Pyrrolo[2,3-d]pyrimidine, 2-methyl-, hydrochloride (1:1))
• 26786-73-2(6-Methyl-7H-pyrrolo[2,3-d]pyrimidine)
• 1989623-62-2(2-chloro-4-methyl-7H-pyrrolo[2,3-d]pyrimidine)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)